Emergent BioSolutions Inc (EBS)
8.97
+0.20
(+2.28%)
USD |
NYSE |
Nov 05, 16:00
8.97
0.00 (0.00%)
After-Hours: 16:16
Emergent BioSolutions Cash from Financing (Quarterly): -50.90M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -50.90M |
| March 31, 2024 | 40.70M |
| December 31, 2023 | 4.70M |
| September 30, 2023 | -43.00M |
| June 30, 2023 | -486.90M |
| March 31, 2023 | -10.50M |
| December 31, 2022 | 353.10M |
| September 30, 2022 | 229.30M |
| June 30, 2022 | -30.70M |
| March 31, 2022 | -70.50M |
| December 31, 2021 | -110.00M |
| September 30, 2021 | -5.00M |
| June 30, 2021 | -3.80M |
| March 31, 2021 | -22.20M |
| December 31, 2020 | -2.30M |
| September 30, 2020 | 87.10M |
| June 30, 2020 | 4.70M |
| March 31, 2020 | -20.00M |
| December 31, 2019 | -57.90M |
| September 30, 2019 | -19.70M |
| June 30, 2019 | 100.10M |
| March 31, 2019 | -58.40M |
| December 31, 2018 | 785.90M |
| September 30, 2018 | 1.70M |
| June 30, 2018 | 3.20M |
| Date | Value |
|---|---|
| March 31, 2018 | -2.10M |
| December 31, 2017 | -32.72M |
| September 30, 2017 | 3.261M |
| June 30, 2017 | 0.765M |
| March 31, 2017 | -22.71M |
| December 31, 2016 | 5.21M |
| September 30, 2016 | -44.51M |
| June 30, 2016 | 15.25M |
| March 31, 2016 | 4.252M |
| December 31, 2015 | 14.91M |
| September 30, 2015 | 3.076M |
| June 30, 2015 | 6.405M |
| March 31, 2015 | 11.00M |
| December 31, 2014 | 3.689M |
| September 30, 2014 | 0.402M |
| June 30, 2014 | 1.909M |
| March 31, 2014 | 192.87M |
| December 31, 2013 | 7.51M |
| September 30, 2013 | 0.647M |
| June 30, 2013 | -0.54M |
| March 31, 2013 | 0.995M |
| December 31, 2012 | -4.317M |
| September 30, 2012 | -0.371M |
| June 30, 2012 | 1.673M |
| March 31, 2012 | 1.25M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-486.90M
Minimum
Jun 2023
353.10M
Maximum
Dec 2022
-10.22M
Average
-10.50M
Median
Mar 2023
Cash from Financing (Quarterly) Benchmarks
| Geovax Labs Inc | 2.734M |
| Tonix Pharmaceuticals Holding Corp | 7.025M |
| Abbott Laboratories | -1.576B |
| SIGA Technologies Inc | -42.87M |
| Chimerix Inc | -0.042M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 47.50M |
| Cash from Investing (Quarterly) | -4.60M |
| Free Cash Flow | 37.60M |
| Free Cash Flow Per Share (Quarterly) | 0.8156 |
| Free Cash Flow to Equity (Quarterly) | 86.60M |
| Free Cash Flow to Firm (Quarterly) | 67.66M |
| Free Cash Flow Yield | 8.03% |